Personalis, Inc. (NASDAQ:PSNL) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.28 per share.
For the full year, analysts predict revenues of $ 77.94 million, while looking forward to loss of $ 1.12 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 77.50 million ~ $ 83.50 million
Click Here For More Historical Outlooks Of Personalis, Inc.
Previous Quarter Performance
Personalis, Inc. reported loss for the second quarter of $ 0.29 per share, from the revenue of $ 19.50 million. The quarterly revenues raised 23.26 percent compared with the same quarter last year. Street analysts expected Personalis, Inc. to report loss of $ 0.34 per share on revenue of $ 16.33 million for the second quarter. The bottom line results beat street analysts by $ 0.05 or 14.71 percent, at the same time, top line results outshined analysts by $ 3.17 million or 19.41 percent.
Stock Performance
Shares of Personalis, Inc. traded low $ -0.09 or -0.34 percent on Wednesday, reaching $ 26.38 with volume of 472.70 thousand shares. Personalis, Inc. has traded high as $ 27.67 and has cracked $ 25.89 on the downward trend
The closing price of $ 26.38, representing a 519.91 % increase from the 52 week low of $ 4.27 and a 14.47 % decrease over the 52 week high of $ 30.95.
The company has a market capital of $ 1.01 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 19th October 2020, initiated by Citigroup at Buy rating, with $ 35.00 target price.
Conference Call
Personalis, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.personalis.com
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies.
